Cefdinir, an FDA-approved antibiotic used to treat conditions such as pneumonia, otitis media, and strep throat35, was demonstrated to significantly reduce the viability of GBO-PDCs with IDH1 wild-type status. Here, IDH1 is linked to susceptibility to pneumonia measurement.